Ocular Hypertension Clinical Trial
Official title:
A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
Glaucoma is the world's the second leading cause of irreversible blindness. The World Health
Organization (WHO) estimated the incidence of blindness due to glaucoma to be 4.4 million
people worldwide in 2002. Intraocular pressure (IOP) is the sole proven modifiable risk
factor for the development and progression of glaucomatous optic neuropathy. Medical therapy
is aimed at lowering IOP in order to prevent or slow progression.
Exfoliation syndrome (XFS) is the most common identifiable cause of open-angle glaucoma,
affecting an estimated 60 to 70 million people worldwide. Approximately two-thirds of
patients have disease in only one eye on clinical examination; however, XFS is detectable in
the other eye with conjunctival biopsy. XFS is also a systemic disease, with effects on the
cardiovascular and cerebrovascular systems.
Patients with XFS are twice as likely to convert from ocular hypertension to glaucoma.
Glaucoma in XFS is more severe than primary open angle glaucoma. There is greater diurnal IOP
fluctuation, greater visual field loss and optic nerve head damage at the time of diagnosis,
poorer response to medications, more rapid visual field progression and more frequent need
for surgery.
Because you meet eligibility criteria for our study, we ask for your consent to participate
in the study described below. In brief, you will be taking an investigational drug (AR-12286,
rho-kinase Inhibitor) at either 0.5% or 0.7% once a day for 6 months. This drug is currently
being tested in patients with primary open-angle glaucoma, but not yet in glaucoma in
exfoliation syndrome. Because of the mechanism of glaucoma in XFS and the mechanism of action
of rho-kinase inhibitors, there is reason to think it would be more effective in eyes with
XFS and glaucoma than in primary open-angle glaucoma (ordinary glaucoma). There will be a
baseline and study day 1 visit, week 1 visit, month 1 and 3 visit, week 13 visit, month 6
visit and a week 25 visit; for a total of 7 office visits.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03284853 -
Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
|
Phase 3 | |
| Completed |
NCT01157364 -
Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06441643 -
Next Generation Rocklatan
|
Phase 2 | |
| Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
| Recruiting |
NCT02792803 -
A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma
|
Phase 4 | |
| Terminated |
NCT02801617 -
Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension
|
Phase 3 | |
| Completed |
NCT02558374 -
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
|
Phase 3 | |
| Completed |
NCT02993445 -
Effect of Alternate Therapies on Intraocular Pressure in Ocular Hypertension
|
N/A | |
| Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A | |
| Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
| Completed |
NCT02338362 -
Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma
|
Phase 4 | |
| Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
| Completed |
NCT02003547 -
A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01995136 -
Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma
|
Phase 4 | |
| Completed |
NCT01664039 -
An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®
|
Phase 4 | |
| Completed |
NCT01693315 -
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
|
Phase 2 | |
| Active, not recruiting |
NCT01430923 -
Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost
|
N/A | |
| Completed |
NCT01415401 -
Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada
|
Phase 4 | |
| Completed |
NCT01489670 -
Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension
|
N/A | |
| Completed |
NCT01410188 -
Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension
|
Phase 1/Phase 2 |